Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...

Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The third quarter was a strong one for the fund ...

Bio-Rad Laboratories Inc. reported its earnings for the second quarter of 2025, revealing a modest increase in net sales and a stable financial performance. Despite a challenging market environment, ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” third-quarter 2025 investor letter. The letter can be downloaded here. The fund returned -0.33% in the third ...

Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” third-quarter 2025 investor letter. The letter can be downloaded here. The fund returned -0.33% in the third ...

LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), and Gencurix, Inc. (KOSDAQ: 229000), announced the signing of a strategic agreement establishing Bio-Rad as the exclusive distributor of Gencurix’ ...

(MENAFN- GlobeNewsWire - Nasdaq) Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE ...